Dr Reddy's Receives US FDA Tentative Approval for Twice-Yearly HIV Prevention Drug
Dr Reddy's Laboratories has received tentative approval from the US FDA for its generic injectable lenacapavir, a twice-yearly HIV prevention drug. Approved under the FDA's PEPFAR program, this milestone enables affordable access across 120 countries outside the US through a voluntary license from Gilead Sciences. Initial supplies are expected by late 2026, with broader rollout planned for 2027. Partnerships with Unitaid, Wits RHI, and CHAI support regulatory and product development efforts to expand access in low- and middle-income nations.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (72/100). Lens Score 50/100.
Outlets measured: thehindu, news18, moneycontrol, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 2 Nov, 03:39 pm. Other outlets followed.